Publication Date: 27 Jul 2011
Journal: Breast Cancer: Basic and Clinical Research
Citation: Breast Cancer: Basic and Clinical Research 2011:5 175-199
doi: 10.4137/BCBCR.S6562
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this review, we aim to give a broad overview of the disease’s nomenclature and epidemiology, as well as the basic mechanisms of emerging targeted therapies and their performance in clinical trials to date.
PDF (665.85 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
PMC HTML
We are delighted about the speedy and professional process.
Facebook Google+ Twitter
Pinterest Tumblr YouTube